AAVantgarde to Present Gene Therapy Updates at EURETINA 2026
News related to:AAVantgarde Bio · 2 min read
MILAN, Sept. 16, 2026 /CourierPR/ -- AAVantgarde Bio, a clinical-stage biotechnology company, will present updated clinical data from its gene therapy programs at the 26th European Society of Retina Specialists (EURETINA) Annual Congress in Vienna from October 1 to 4, 2026. The company’s dual-AAV technology aims to treat inherited retinal diseases, including Usher syndrome type 1B and Stargardt disease.
At the congress, AAVantgarde will deliver an oral presentation on the LUCE-1 Phase 1/2 study, which evaluates the safety and efficacy of a single sub-retinal administration of AAVB-081, a dual hybrid AAV-based gene therapy, for patients with retinitis pigmentosa associated with Usher syndrome type 1B. The study is led by Professor Francesca Simonelli, Head of the Ophthalmology Unit at the University Hospital of Campania “Luigi Vanvitelli” in Naples. This presentation will be part of the Free Paper 47 - Inherited Retinal Disease session on October 4, 2026, from 13:00 to 13:20 CEST.
The LUCE-1 presentation has been shortlisted for the 2026 August Deutman Award for Best Free Paper, recognizing the best Free Paper presented at the EURETINA Annual Congress. The award winner will be announced during the EURETINA Opening Ceremony on October 1, 2026.
Additionally, Professor Paulo Eduardo Stanga, Professor of Ophthalmology at the UCL Institute of Ophthalmology and Founder & Chief Medical Officer of The Retina Clinic London, will present AAVB-039, a dual AAV8.ABCA4 gene therapy program for Stargardt disease (STGD1). The presentation will include preclinical data and an overview of the CELESTE Phase 1/2 clinical study design. This session is scheduled for October 4, 2026, from 12:00 to 12:06 CEST, as part of the Free Paper 45 - Inherited Retinal Disease session.
AAVantgarde will also be available for partnering and scientific discussions throughout the congress. The company’s lead programs target Stargardt disease and retinitis pigmentosa due to Usher syndrome type 1B, two severe, inherited retinal diseases with no approved treatments. With a strong foundation in translational science and a commitment to clinical excellence, AAVantgarde is working to bring transformative therapies to patients.